130 related articles for article (PubMed ID: 19716955)
1. Rivaroxaban versus enoxaparin after total knee arthroplasty.
Gómez-Outes A; Suárez-Gea ML; Blázquez-Pérez A; Pozo-Hernández C; Vargas-Castrillón E
Lancet; 2009 Aug; 374(9691):682; author reply 683. PubMed ID: 19716955
[No Abstract] [Full Text] [Related]
2. Interpretation of benefit-risk of enoxaparin as comparator in the RECORD program: rivaroxaban oral tablets (10 milligrams) for use in prophylaxis in deep vein thrombosis and pulmonary embolism in patients undergoing hip or knee replacement surgery.
Van Thiel D; Kalodiki E; Wahi R; Litinas E; Haque W; Rao G
Clin Appl Thromb Hemost; 2009; 15(4):389-94. PubMed ID: 19608550
[TBL] [Abstract][Full Text] [Related]
3. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Lassen MR; Ageno W; Borris LC; Lieberman JR; Rosencher N; Bandel TJ; Misselwitz F; Turpie AG;
N Engl J Med; 2008 Jun; 358(26):2776-86. PubMed ID: 18579812
[TBL] [Abstract][Full Text] [Related]
4. Rivaroxaban versus enoxaparin after total knee arthroplasty.
Longo UG; Maffulli N; Denaro V
Lancet; 2009 Aug; 374(9691):681-2; author reply 683. PubMed ID: 19716953
[No Abstract] [Full Text] [Related]
5. Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials.
Nieto JA; Espada NG; Merino RG; González TC
Thromb Res; 2012 Aug; 130(2):183-91. PubMed ID: 22425218
[TBL] [Abstract][Full Text] [Related]
6. Rivaroxaban versus enoxaparin after total knee arthroplasty.
Raju NC; Dimmitt S; Eikelboom JW
Lancet; 2009 Aug; 374(9691):681; author reply 683. PubMed ID: 19716954
[No Abstract] [Full Text] [Related]
7. Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials.
Huisman MV; Quinlan DJ; Dahl OE; Schulman S
Circ Cardiovasc Qual Outcomes; 2010 Nov; 3(6):652-60. PubMed ID: 20923996
[TBL] [Abstract][Full Text] [Related]
8. Rivaroxaban versus enoxaparin after total knee arthroplasty.
Stief T
Lancet; 2009 Aug; 374(9691):681; author reply 683. PubMed ID: 19716952
[No Abstract] [Full Text] [Related]
9. Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials.
Cao YB; Zhang JD; Shen H; Jiang YY
Eur J Clin Pharmacol; 2010 Nov; 66(11):1099-108. PubMed ID: 20812009
[TBL] [Abstract][Full Text] [Related]
10. The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: results from the RECORD programme.
Lassen MR; Gent M; Kakkar AK; Eriksson BI; Homering M; Berkowitz SD; Turpie AG
J Bone Joint Surg Br; 2012 Nov; 94(11):1573-8. PubMed ID: 23109641
[TBL] [Abstract][Full Text] [Related]
11. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
Turpie AG; Lassen MR; Davidson BL; Bauer KA; Gent M; Kwong LM; Cushner FD; Lotke PA; Berkowitz SD; Bandel TJ; Benson A; Misselwitz F; Fisher WD;
Lancet; 2009 May; 373(9676):1673-80. PubMed ID: 19411100
[TBL] [Abstract][Full Text] [Related]
12. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
Eriksson BI; Borris LC; Friedman RJ; Haas S; Huisman MV; Kakkar AK; Bandel TJ; Beckmann H; Muehlhofer E; Misselwitz F; Geerts W;
N Engl J Med; 2008 Jun; 358(26):2765-75. PubMed ID: 18579811
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of thromboprophylaxis with low-molecular-weight heparin or rivaroxaban in hip and knee replacement surgery: findings from the ORTHO-TEP registry.
Beyer-Westendorf J; Lützner J; Donath L; Tittl L; Knoth H; Radke OC; Kuhlisch E; Stange T; Hartmann A; Günther KP; Weiss N; Werth S
Thromb Haemost; 2013 Jan; 109(1):154-63. PubMed ID: 23197272
[TBL] [Abstract][Full Text] [Related]
14. BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study.
Turpie AG; Fisher WD; Bauer KA; Kwong LM; Irwin MW; Kälebo P; Misselwitz F; Gent M;
J Thromb Haemost; 2005 Nov; 3(11):2479-86. PubMed ID: 16241946
[TBL] [Abstract][Full Text] [Related]
15. A comparison of complications requiring return to theatre in hip and knee arthroplasty patients taking enoxaparin versus rivaroxaban for thromboprophylaxis.
Chahal GS; Saithna A; Brewster M; Gilbody J; Lever S; Khan WS; Foguet P
Ortop Traumatol Rehabil; 2013; 15(2):125-9. PubMed ID: 23652532
[TBL] [Abstract][Full Text] [Related]
16. Rivaroxaban (Xarelto)--a new oral anticoagulant.
Med Lett Drugs Ther; 2011 Aug; 53(1371):65-7. PubMed ID: 21860366
[No Abstract] [Full Text] [Related]
17. Rivaroxaban for thromboprophylaxis.
Lotke PA
N Engl J Med; 2008 Nov; 359(20):2174; author reply 2175-6. PubMed ID: 19009675
[No Abstract] [Full Text] [Related]
18. Incidence of neuraxial haematoma after total hip or knee surgery: RECORD programme (rivaroxaban vs. enoxaparin).
Rosencher N; Llau JV; Mueck W; Loewe A; Berkowitz SD; Homering M
Acta Anaesthesiol Scand; 2013 May; 57(5):565-72. PubMed ID: 23336294
[TBL] [Abstract][Full Text] [Related]
19. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
Stevenson M; Scope A; Holmes M; Rees A; Kaltenthaler E
Health Technol Assess; 2009 Oct; 13 Suppl 3():43-8. PubMed ID: 19846028
[TBL] [Abstract][Full Text] [Related]
20. Oral rivaroxaban for symptomatic venous thromboembolism.
; Bauersachs R; Berkowitz SD; Brenner B; Buller HR; Decousus H; Gallus AS; Lensing AW; Misselwitz F; Prins MH; Raskob GE; Segers A; Verhamme P; Wells P; Agnelli G; Bounameaux H; Cohen A; Davidson BL; Piovella F; Schellong S
N Engl J Med; 2010 Dec; 363(26):2499-510. PubMed ID: 21128814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
